US-based integrated digital health solutions company Recuro Health (Recuro) has secured an additional investment of $47m in a Series B funding round.

This investment round saw participation from existing and new investors.

Some of the key investors include Flippen Group, 4D Capital, GPG Ventures and ARCH Venture Partners.

The company will utilise this investment to facilitate advancement and scaling of its Digital Medical Home, which comprises diagnostic-enabled Virtual Primary Care as well as Virtual Behavioural Health Solutions.

Designed to meet the healthcare needs of the population, Recuro’s Digital Medical Home solution is a combination of advanced science, at-home diagnostics, data and targeted genomics capabilities, including cancer screening and pharmacogenomics, to support integrated care.

ARCH Venture Partners co-founder and managing director Robert Nelsen said: “Recuro is proving to be the best of breed in the intersection of science, diagnostics and digital health.

“This nimble organisation has the ability to quickly respond to market changes, scale its tech-enabled services and close gaps in care that improve population health. We see significant opportunities for exceptional growth and continued success.”

Established in 2021, Recuro is an early-stage technology venture company that aims to transition existing healthcare systems in the US from a ‘reactive and disease-focused’ approach to a ‘proactive care’ model.

Recuro Health CEO and founder Michael Gorton said: “The continued support of our investors is a clear sign of their confidence in our mission.

“We have an extraordinary team at Recuro dedicated to evolving healthcare to be more proactive and personal, resulting in improved outcomes, better patient engagement and lower costs.

“In this next phase of our company growth and expansion, we are committed to building upon the success of our Digital Medical Home and continuing to advance the next generation of digital care services.”